Our client base consists of pubic traded companies in Europe, North America and Australia. The total universe of biotechnology companies that we follow on a daily basis comprises around 200 companies.
Biofrontera (B8F.DE): Research Note
Biofrontera AG (B8F.DE, B8F.L) is a biopharmaceutical company specializing in the development of dermatological drugs. Its lead product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate actinic keratosis (AK) on the face and scalp in conjunction with photodynamic therapy (PDT).
Please contact us if you are interested in research on either of these companies or on other companies in our universe.
Resverlogix (RVX.TO): Initiating Coverage Report
Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients.
Immuron (IMC.AX): Initiating Coverage Report
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system. Its lead program is IMM-124E which is currently in Phase II for fatty liver-diseases NASH (non-alcoholic steatohepatitis) and ASH (alcoholic steatohepatitis). Its second program, IMM-529, is in development to target the Clostridium difficile bacterium. We have increased our valuation calculation following a rerating of both its programs in NASH and CDI. Especially in NASH, the potential deal size has increased following recent activity in the area. In our view, the company’s current total value should be AUD 197 million, or AUD 1.92 per share compared to our previous calculation of AUD 75 million.